Skip to main content

Advertisement

SpringerLink
Log in

Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine

  • Clinical Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Bevacizumab (BEV) is widely used for treatment of patients with recurrent glioblastoma multiforme (GBM). 1-(2-Chlorethyl)-cyclohexyl-nitrosourea (CCNU, lomustine) monotherapy is an approved chemotherapeutical option for recurrent GBM. Recent evidence demonstrated a survival benefit of combined treatment with BEV and CCNU in patients with a first recurrence of GBM. We examined the outcome of recurrent GBM patients with BEV monotherapy versus BEV/CCNU therapy when used as last-line therapy. 35 patients with recurrent GBM treated between 2010 and 2014 were included in this retrospective study. Progression-free and overall survival was determined with reference to the beginning of BEV or BEV/CCNU therapy and initial diagnosis. 17 patients received BEV monotherapy, 18 patients received combined BEV and CCNU therapy. The impact of parameters such as IDH mutation, MGMT promoter methylation, tumor localization, histology and the number of surgeries were included in a multivariate ANOVA analysis. Furthermore, Karnofsky performance score (KPS), neurological function and toxicity were assessed. BEV/CCNU treatment led to an extension of PFS (6.11 months; 95 % CL 3.41–12.98 months; log-rank p = 0.00241) and OS (6.59 months; 95 % CL 5.51–16.3 months; log-rank p = 0.0238) of 2 months compared to BEV monotherapy. This survival advantage was independent of histology, IDH mutation status or the number of previous surgeries. Neurological function, KPS and toxicity were not significantly different between both treatment groups. Last-line therapy with BEV/CCNU results in a longer PFS and OS compared to BEV monotherapy and is well-tolerated. These findings confirm the role of these agents in the treatment of recurrent GBM and are in line with other studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Batchelor TT, Sorensen AG, di Tomaso E, Zhang W-T, Duda DG, Cohen KS et al (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83–95. doi:10.1016/j.ccr.2006.11.021

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  2. Von Baumgarten L, Brucker D, Tirniceru A, Kienast Y, Grau S, Burgold S et al (2011) Bevacizumab has differential and dose-dependent effects on glioma blood vessels and tumor cells. Clin Cancer Res 17:6192–6205. doi:10.1158/1078-0432.CCR-10-1868

    Article  Google Scholar 

  3. Brandsma D, van den Bent MJ (2009) Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr Opin Neurol 22:633–638. doi:10.1097/WCO.0b013e328332363e

    Article  PubMed  Google Scholar 

  4. Brennan CW, Verhaak RGW, McKenna A, Campos B, Noushmehr H, Salama SR et al (2013) The somatic genomic landscape of glioblastoma. Cell 155:462–477. doi:10.1016/j.cell.2013.09.034

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  5. Chen R, Ravindra VM, Cohen AL, Jensen RL, Salzman KL, Prescot AP et al (2015) Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas. Neurosurg Focus 38:E2. doi:10.3171/2015.1.FOCUS14745

    Article  PubMed  Google Scholar 

  6. Chinot OL, Wick W, Cloughesy T (2014) Bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:2049

    Article  PubMed  Google Scholar 

  7. Claus EB, Walsh KM, Wiencke JK, Molinaro AM, Wiemels JL, Schildkraut JM et al (2015) Survival and low-grade glioma: the emergence of genetic information. Neurosurg Focus 38:E6. doi:10.3171/2014.10.FOCUS12367

    Article  PubMed  PubMed Central  Google Scholar 

  8. Ding S-S, Li L, Yu C-X (2014) Systematic evaluation of bevacizumab in recurrent ovarian cancer treatment. J BUON 19:965–972

    PubMed  Google Scholar 

  9. Dolecek TA, Propp JM, Stroup NE, Kruchko C (2012) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro-Oncology. doi:10.1093/neuonc/nos218

    Google Scholar 

  10. Field KM, Jordan JT, Wen PY, Rosenthal MA, Reardon DA (2014) Bevacizumab and glioblastoma: scientific review, newly reported updates, and ongoing controversies. Cancer. doi:10.1002/cncr.28935

    PubMed  Google Scholar 

  11. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733–4740. doi:10.1200/JCO.2008.19.8721

    Article  PubMed  CAS  Google Scholar 

  12. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA et al (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:699–708. doi:10.1056/NEJMoa1308573

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  13. Guan X, Vengoechea J, Zheng S, Sloan AE, Chen Y, Brat DJ et al (2014) Molecular subtypes of glioblastoma are relevant to lower grade glioma. PLoS ONE 9:e91216. doi:10.1371/journal.pone.0091216

    Article  PubMed  PubMed Central  Google Scholar 

  14. Piccioni DE, Selfridge J, Mody RR, Chowdhury R, Li S, Lalezari S et al (2014) Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy. Neuro-Oncology 16(6):815–822. doi:10.1093/neuonc/nou028

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  15. Lu KV, Chang JP, Parachoniak CA, Pandika MM, Aghi MK, Meyronet D et al (2012) VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 22:21–35. doi:10.1016/j.ccr.2012.05.037

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  16. Moen MD (2010) Bevacizumab: in previously treated glioblastoma. Drugs 70:181–189. doi:10.2165/11203890-000000000-00000

    Article  PubMed  CAS  Google Scholar 

  17. Mrugala MM, Crew LK, Fink JR, Spence AM (2012) Carboplatin and bevacizumab for recurrent malignant glioma. Oncol Lett 4:1082–1086. doi:10.3892/ol.2012.839

    PubMed  CAS  PubMed Central  Google Scholar 

  18. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP et al (2010) Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17:510–522. doi:10.1016/j.ccr.2010.03.017

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  19. Parsons DW, Jones S, Zhang X, Lin JC-H, Leary RJ, Angenendt P et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science (New York, NY) 321:1807–1812. doi:10.1126/science.1164382

    Article  CAS  Google Scholar 

  20. Reardon DA, Desjardins A, Peters KB, Vredenburgh JJ, Gururangan S, Sampson JH et al (2011) Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Cancer 117:5351–5358. doi:10.1002/cncr.26188

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  21. Reinmuth N, Heigener D, Reck M (2015) Novel angiogenesis inhibitors in nonsmall cell lung cancer. Curr Opin Oncol 27:79–86. doi:10.1097/CCO.0000000000000166

    Article  PubMed  CAS  Google Scholar 

  22. Stewart LA (2002) Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359:1011–1018. doi:10.1016/S0140-6736(02)08091-1

    Article  PubMed  CAS  Google Scholar 

  23. Stupp R, Mason W, van den Bent MJ, Weller M, Fisher BM, Taphoorn MJB et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. doi:10.1056/NEJMoa043330

    Google Scholar 

  24. Stupp R, Weller M (2014) Questions regarding the optimal use of bevacizumab in glioblastoma: a moving target. Neuro-oncology 16:765–767. doi:10.1093/neuonc/nou092

    Article  PubMed  PubMed Central  Google Scholar 

  25. Taal W, Oosterkamp HM, Walenkamp AME, Dubbink HJ, Beerepoot LV, Hanse MCJ et al (2014) Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol 15:943–953. doi:10.1016/S1470-2045(14)70314-6

    Article  PubMed  CAS  Google Scholar 

  26. Venneti S, Huse JT (2015) The evolving molecular genetics of low-grade glioma. Adv Anat Pathol 22:94–101. doi:10.1097/PAP.0000000000000049

    Article  PubMed  CAS  Google Scholar 

  27. Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98–110. doi:10.1016/j.ccr.2009.12.020

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  28. Vredenburgh JJ, Desjardins A, Herndon JE, Marcello J, Reardon DA, Quinn JA et al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722–4729. doi:10.1200/JCO.2007.12.2440

    Article  PubMed  CAS  Google Scholar 

  29. Wick A, Felsberg J, Steinbach JP, Herrlinger U, Platten M, Blaschke B et al (2007) Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol 25:3357–3361. doi:10.1200/JCO.2007.10.7722

    Article  PubMed  CAS  Google Scholar 

  30. Wiestler B, Radbruch A, Osswald M, Combs SE, Jungk C, Winkler F et al (2014) Towards optimizing the sequence of bevacizumab and nitrosoureas in recurrent malignant glioma. J Neurooncol 117:85–92. doi:10.1007/s11060-013-1356-3

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Medical Center - University of Freiburg, BreisacherStrasse 64, 79106, Freiburg, Germany

    D. H. Heiland, W. Masalha, P. Franco, M. R. Machein & A. Weyerbrock

Authors
  1. D. H. Heiland
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. Masalha
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. Franco
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. R. Machein
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Weyerbrock
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Weyerbrock.

Ethics declarations

Conflict of interest

Author AW has received honorarium from Roche Pharma AG and was a member of the scientific advisory board at Roche Pharma AG.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Heiland, D.H., Masalha, W., Franco, P. et al. Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine. J Neurooncol 126, 567–575 (2016). https://doi.org/10.1007/s11060-015-2002-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-015-2002-z

Keywords

Search

Navigation